PHA-680626
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


PHA-680626
Description :
PHA-680626 is an effective inhibitor of the interaction between Aurora-A and N-Myc. PHA-680626 inhibits kinase activity of AURKA and Bcr-Abl, and induces N-Myc degradation. PHA-680626 decreases phosphorylation of CrkL and histone H3. PHA-680626 shows anti-proliferative and pro-apoptotic activity on Imatinib (HY-15463) -resistant chronic myeloid leukemia cell lines and primary CD34+ cells[1].CAS Number :
[398493-74-8]UNSPSC :
12352005Target :
Apoptosis; Aurora Kinase; Bcr-Abl; c-Myc; Histone MethyltransferaseType :
Reference compoundRelated Pathways :
Apoptosis; Cell Cycle/DNA Damage; Epigenetics; Protein Tyrosine Kinase/RTKField of Research :
CancerAssay Protocol :
https://www.medchemexpress.com/pha-680626.htmlSmiles :
O=C(NC1=NNC2=C1CN(C(CC3=CC=CS3)=O)C2)C4=CC=C(N5CCN(C)CC5)C=C4Molecular Formula :
C23H26N6O2SMolecular Weight :
450.56References & Citations :
[1]Boi D, et al. PHA-680626 Is an Effective Inhibitor of the Interaction between Aurora-A and N-Myc. Int J Mol Sci. 2021 Dec 4;22 (23) :13122. |[2]Gontarewicz A, et al. PHA-680626 exhibits anti-proliferative and pro-apoptotic activity on Imatinib-resistant chronic myeloid leukemia cell lines and primary CD34+ cells by inhibition of both Bcr-Abl tyrosine kinase and Aurora kinases. Leuk Res. 2008 Dec;32 (12) :1857-65.Shipping Conditions :
Room temperatureScientific Category :
Reference compound1Clinical Information :
No Development Reported

